U.S. House Passes Arrington-Spanberger-Boyle Bill to Increase Negotiation Transparency, Lower Costs of Prescription Drugs

WASHINGTON – Today, the U.S. House of Representatives voted 403-0 to pass the Public Disclosure of Drug Discounts Act (H.R. 2115) – bipartisan legislation introduced by Congressman Jodey Arrington (TX-19), Congresswoman Abigail Spanberger (VA-7), and Congressman Brendan Boyle (PA-2) to provide greater transparency to the discounts negotiated between insurance companies and drug manufacturers through Pharmaceutical Benefit Managers (PBMs). The legislation also includes the text of Congressman Arrington’s Shop Rx Act introduced in June 2019, which ensures that Medicare drug plans offer real-time benefit information to seniors.

“One of the reasons why drug costs have spiraled out of control is because discounts negotiated by the PBMs – the middle-men in the drug supply chain – are shrouded in secrecy,” said Arrington.

“Americans are left in the dark about the rebates these PBMs negotiate with drug manufacturers, and we have no idea where the rebate value is going, but we know where it’s not going – to our seniors at the point of sale. This legislation will help ensure that rebates go towards reducing the cost of drugs for seniors, as well as the cost to the American taxpayer.”